Mutations of human MID1 are associated with X-linked Opitz G Syndrome (XLOS), which is characterized by midline birth defects. XLOS-observed mutations within the MID1 B-box1 domain are associated with cleft lip/ palate, wide-spaced eyes and hyperspadias. Three of the four XLOSobserved mutations in the B-box1 domain results in unfolding but the structural and functional effects of the P151L mutation is not characterized. Here, we demonstrate that the P151L mutation does not disrupt the overall tertiary structure of the B-box1 domain and the adjacent domains. In fact, MID1 E3 ligase activity is slightly enhanced. However, the P151L mutation disrupted the ability of MID1 to catalyze the poly-ubiquitination of alpha4, a novel regulator of PP2A. This observation is consistent with results observed with the other three structure-destabilizing B-box1 mutations in targeting alpha4 but not PP2A. Alpha4 is shown to bind and sequester the catalytic subunit of PP2A and protect it from MID1-mediated ubiquitination and as a result, an increase in alpha4 can contribute to an increase in PP2A, playing a greater role in midline development during embryogenesis.
Introduction
X-linked Opitz G Syndrome (XLOS) is characterized by defects along the ventral midline region that include abnormalities of the brain, craniofacial region and genitalia [1] [2] [3] [4] [5] . Among the more common defects are cleft lip/palate, hyperterlorism and hypersadias. These abnormalities are associated with frame shifts, truncations, deletions and point mutations within the MID1 protein. A table listing these mutations with reported abnormalities is available in a recent publication [1] .
MID1 is a microtubule-associated protein that belongs to the tripartite motif (TRIM) family of proteins, characterized by their N-terminal really interesting new gene (RING), B-box, and Coiled coil domains [6] . There are nine subfamilies of TRIM proteins, each differentiated by variations of their C-terminal domains [6] . MID1 belongs to the C-Ι subfamily consisting of the C-terminal subgroup One Signature box, Fibronectin III and B30.2 domains [6] . The function of the C-terminal half of MID1 is not fully understood but contributes to microtubule and other proteinprotein interactions [6, 7] .
Our studies have shown that the RING and B-box domains function as ubiquitin E3 ligases [8] . E3 ligase functionality is important for targeting proteins to the proteasome for degradation, recycling and regulation [9, 10] . Mainly, the RING, B-box1 and B-box2 domains function synergistically to catalyze the ubiquitination of the catalytic subunit of PP2A (PP2Ac), its regulatory subunit alpha4 and the fused (Fu) kinase [1, [11] [12] [13] . PP2A is an essential mammalian serine/threonine phosphatase that regulates, among many, metabolism, cell-cycle progression and cell death [14] [15] [16] [17] . Mammalian alpha4 protein is shown to down-regulate PP2Ac in the target of rapamycin (TOR) pathway [18] [19] [20] . Whether by a similar mechanism, alpha4 also regulates the homeostasis of PP2Ac [1] with its N-terminal domain binding and sequestering PP2Ac [13] . The alpha4-PP2Ac complex is believed to block the site of MID1-mediated ubiquitination [13] . Furthermore, the C-terminal domain of alpha4 binds to MID1 and down regulates MID1 E3 ligase activity [11, 21] .
The B-box1 domain is critical for poly-ubiquitination of alpha4 and PP2Ac [1, 11] . The structure of the Bbox1 domain is similar to RING E3 ligase domains [22] [23] [24] [25] [26] , consisting of two b-strands and one a-helix and held together by the coordination of two zinc ions (Fig. 1) . The zinc ions are coordinated by cysteine and histidine residues located on loops 1 and 2. We recently showed that the A130T, C142S and C145T XLOSobserved mutations resulted in complete unfolding of the tertiary structure and disrupted MID1 E3 ligase function and targeting of alpha4 [1, 27] . Residues C142 and C145 coordinate one of the two zinc ions so it was not surprising that replacing these residues with ones that do not coordinate zinc ions resulted in unfolding of the structure. Residue A130 is located~3-5
A away from one of the two zinc sites and is not directly involved in zinc-coordination but its mutation to threonine or valine also lead to complete domain unfolding. Molecular dynamics studies suggested that the bulkier threonine and valine residues caused an increase in solvation and pKa values of the zinc-binding cysteines, thereby disrupting the ability of the cysteines to coordinate the zinc ion [28] . The effect of the mutation of the XLOS-observed proline 151 to leucine (P151L) is less obvious given its location at the end of the a-helix.
Here, we demonstrate that the P151L mutation has little effect on the overall structure or E3 ligase activity of the B-box1 domain. Instead, the mutation affected the ability of MID1 to catalyze the poly-ubiquitination of alpha4. These studies indicate that residue P151 is important for the binding and targeting of alpha4.
Results
As noted, the P151L mutation found within the B-box1 domain is associated with numerous midline birth defects [1] . Examination of the structure of the B-box1 domain reveals that residue P151 is not involved in extensive stabilizing interactions but is adjacent to residue H150, which coordinates one of the two zinc ions (Fig. 1A) . Given its location, it was unclear how this mutation would affect zinc coordination and the overall structure of the B-box1 domain (Fig. 1A) . We introduced the P151L mutation within the isolated Bbox1 domain and natively tandem RING-B-box1 (RB1), RING-B-box1-B-box2 (RB1B2) and B-box1-B-box2 (B1B2) domains to investigate its structural and functional effects.
The P151L mutant B-box1 domain maintains its overall fold
To understand the structural effect of the mutation, we acquired 2D NMR 1 Fig. 2A) . A rapid way to evaluate structural perturbation is to compare peak positions of the HSQC spectra of the mutant and wild-type B-box1 proteins. The superposition of the spectra reveals that the majority of peaks overlap indicating that the chemical environment of the corresponding amino acids is the same and confirming that the overall structure of the mutant B-box1 domain is essentially unchanged. There are 16 amino acids (Q120, K132, C134, V135, V139, C145, K147, A148, T149, H150, K153, K154, F156, T157, G158, H159) whose peaks do not overlap, indicated by arrows. The chemical shift differences for most of these residues are relatively small (< 0.25 p.p.m.), indicating minor if any structural changes. Three residues, K153, G158 and T157, appear to experience significant conformational changes, as indicated by the large chemical shift changes in the P151L mutant B-box1 domain. Of the 16 peaks, seven (V135, V139, T149, K153, K154, T157, G158) show two 1 H-15 N peaks each that most likely arise from the slow exchange between two conformations ( Fig. 2A) . Integration of the two peaks of these seven residues revealed they are essentially equal in intensity and volume.
In addition, there are 11 extra peaks that could not be assigned. The 3D-NOESY data do not show any sequential or long-range correlations indicating that these residues may be part of a small percentage of unfolded protein, not necessarily caused by the mutation but simply by the instability of the P151L mutant B-box1 domain. These peaks could also be the second peak from other amino acids in slow exchange. However, their identity cannot be verified.
Next, we investigated the effect of the mutation on the interaction and structure with the adjacent B-box2 domain because P151 is part of the loop2 region of B-box1. While loop2 contains the zinc binding H159 residue, it is, however, part of the 14-amino acid region that leads into the start of the B-box2 domain (Fig. 1B) . The two B-box domains interact and adopt a structure reminiscent of RING dimers (Fig. 1B) [29] . In contrast, the RING domain is separated by 45-unstructured amino acids from the B-box1 domain and current and previous results indicate little interaction between these domains. Given the interaction and short linker between the B-box domains, it is unclear how the P151L mutation would affect the two B-box domains.
Overlay of the HSQC spectra of the P151L mutant and wild-type B1B2 domains revealed that the pattern of peaks between the mutant and wild-type B-box1 domain was very similar with that of the isolated domains (Fig. 2B) . Interestingly, most of the residues except V139, T149 and K154 show a single peak. For these three residues, the two peaks were almost overlapping with one peak significantly stronger than the other. Integration revealed their volume ratio was approximately 80 : 20. To identify if the B-box2 domain was still folded and its interaction with the B-box1 domain was unchanged, we compared the HSQC spectrum of the mutant B1B2 protein to that of the isolated Bbox2 domain (Fig. 2B, blue) . Peaks for the B-box2 domain within the B1B2 domain structure overlay very well with peaks of the isolated B-box2 domain indicating that both the structure of B-box2 domain and its interaction with the B-box1 domain are unperturbed (Fig. 2B) . 
The P151L B-box1 mutant maintains its E3 ligase activity
In light of the NMR data indicating small, localized structural changes, and the observation that the P151L mutation is associated with birth defects, we next investigated whether the mutation has any effect on the B-box1 E3 ligase activity. As routinely done, E3 ligase activity is confirmed by performing auto-ubiquitination assays. The auto-ubiquitination data reveal that the P151L B-box1 domain maintains E3 ligase activity (Fig. 3A) . The band corresponding to the mono-ubiquitinated (mono-ub) product is brighter in the western blot indicating a greater amount of monoub product (Figs 3 and 4A, ln 7) . In contrast, the band intensity of mono-ub product for the native B-box1 domain (Figs 3 and 4A, ln 6) is significantly less intense, indicating less auto-ubiquitinated product.
Next, we investigated the effect of the mutation using the larger RB1, RB1B2 and B1B2 MID1 domains. Consistent with previous observations [8] , the wild-type RB1 and RB1B2 domains catalyzed poly auto-ubiquitinated (poly-ub) products as indicated by the high molecular weight smearing observed by western blot (Figs 3A and 4A, lns 8, 10). The B1B2 domains possess only mono auto-ubiquitinated activity. Interestingly, the tandem RB1 and RB1B2 domains with the P151L mutation showed similar types of activities as the wild-type versions. The most notable difference between the native and mutant RB1 and RB1B2 proteins is the intensity of the mono-ub bands, which are much brighter for the mutant proteins (Fig. 3A , and 4A, lns 9, 11). The high molecular weight products are less obvious because of the significantly brighter band intensity of the monoubiquitinated product.
The P151L mutation affects the targeting and poly-ubiquitination of alpha4
Since the P151L mutation did not affect the structure or the auto E3 ligase activity of the B-box1 domain, we next investigated whether it has any effect on substrate targeting. As shown previously, the B-box1 domain is required for the binding and poly-ubiquitination of alpha4 but not PP2A [1, 11] . As part of a B1B2 tandem protein, the B-box1 domain catalyzed only a small amount of mono-ub products of alpha4. In contrast, in tandem with the RING domain, the B-box1 domain facilitated poly-ub products [11] .
Results of the ubiquitination assays of alpha4 with the mutant P151L RB1 and RB1B2 proteins showed no poly-ubiquitinated products compared to wild-type proteins (Figs 3 and 4B) . Mono-ubiquitinated alpha4 is observed and this is consistent with results observed when using just the RING domain as the E3 ligase [11] . The alpha4 mono-ub band observed with the B1B2 domains was not present or the intensity was significantly weaker with the mutant protein (Fig. 3B) . It should be noted that the intensity of the alpha4 bands in Figs 3 and 4B appears to decrease from lane four to nine. Analysis of the western blot image revealed the band intensities of alpha4 for each pairing of wild-type and mutant proteins were similar (Fig. 3C) . In lanes 4 and 5, the areas of the alpha4 bands were the same while there was a~20% decrease between the other pairs (Fig. 3C) . Given that all the experiments were performed using the same stock and amount of alpha4, we attributed this decrease to the western blot transfer process. Similar results have been observed with our other western blots (Fig. 4) . Despite this discrepancy, the~20% decrease still could not account for the loss of polyubiquitination observed with the RB1B2 P151L or the mono-ubiquitination of the B1B2 P151L proteins. These observations are reproducible (Fig. 4) . We have repeated the auto-and substrate ubiquitination and observed that the P151L mutation resulted in an increase in mono-autoubiquitination and loss of alpha4 poly-ubiquitination (Fig. 4) .
Discussion
The B-box1 domain of MID1 plays a critical role in both E3 ligase activity and substrate targeting and ubiquitination. We have shown that the B-box1 domain adopts a similar RING fold but only exhibits weak E3 ligase activity compared to RING E3 ligases [8, 25] . In contrast, the tandem RB1 domains exhibit significantly greater E3 ligase activity compared to the RING domain alone [8] . The B-box1 domain is also critical for the poly-ubiquitination of alpha4 and catalytic subunit of PP2A (PP2Ac) [1, 11] . Interestingly, the XLOS-observed A130T/V, C142S and C145T Fig. 4 . Reproducibility of P151L auto-and substrate ubiquitination activities. Assays were repeated to demonstrate that autoand substrate ubiquitination were reproducible and that variation in band intensities in Fig. 3 are due to the process of western blot inconsistencies. (A) Autoubiquitination activity: lanes 1-5 are control experiments in which specific components of the assay were omitted. Lanes 6-13 are auto-ubiquitination activities of wild-type and P151L mutant B-box1, RB1, RB1B2 and B1B2 domains. (B) Ubiquitination of alpha4 using wild-type and P151L mutant RB1 (lanes 5 and 6), RB1B2 (lanes 3 and 4) and B1B2 (lanes 1 and 2) domains. Lanes 7-12 represent control experiments: lane 9 alpha4 was omitted.
mutations lead to the complete loss of poly-ubiquitination of alpha4 [1] . In contrast, when using RB1B2 with these three mutations, poly-ubiquitination of PP2Ac was still observed, indicating that the B-box2 domain could compensate for loss of function of the B-box1 domain. However, the mutant RB1B2 could not polyubiquitinate alpha4, indicating that the B-box1 domain is required for the targeting of alpha4 [1] .
Similar to the A130T/V, C142S and C145T mutations, the P151L mutation is also associated mainly with hypertelorism, hyperspadias and Laryngotracheoesophageal defects [1] . Sequence alignment analysis of the C-Ι subfamily of TRIM proteins revealed residue P151 to be conserved (Fig. 5A ). This proline is located at the end of the a-helix and the beginning of loop2 ( Figs 1A and 5B) and may be important for the positioning of loop2. Usually, proline residues can undergo slow cis-trans isomerization, leading to two conformations for adjacent residues. The lack of two HSQC signals for adjacent residues with the wild-type B-box1 domain suggests that P151, with its rigid backbone structure, has a defined orientation. In contrast, the mutation to leucine leads to seven amino acids undergoing slow exchange between two conformations, as depicted by the observation of two HSQC peaks for these residues (Fig. 2A) . These pairs of peaks are equal in intensity and volume indicating the movement was restricted to a slow conformation realm and that these residues exist in two equally populated states. While we cannot fully verify how the mutation affected the structure of loop2 or these residues based on our NMR data, we can only hypothesize that the removal of the rigid proline would have allowed for a greater degree of movement for residues of loop2. We postulate that the movement is still restricted largely due to residues (H150, H159) at both ends of the loop2 involved in coordinating a zinc ion (Fig. 1A) , and limiting the degree of orientation for the intervening residues. The two conformations of residues of loop2 (K153, K154, T157, G158) correlate with two conformations of residues (V135, V139, T149) adjacent to zinc-coordinating residues suggesting concerted movements.
As part of the B1B2 complex, most of these pairs of peaks have merged to one indicating the presence of the B-box2 domain prevented sampling of the other conformation. However, residues V139, T149 and K154 still showed two peaks that are not as well separated as observed within the isolated P151L B-box1 domain . As noted, one of the two peaks are four times larger than the other indicating that for these residues there is a more predominant conformation, supporting that the presence of the B-box2 domain restricts conformational flexibility arising from the P151L mutation.
The position of loop2 is very important for E3 ligase activity [30] [31] [32] [33] . Superposition of the structures of the B-box1 domain with a known RING domain (Fig. 5B) , reveals different orientations for loop2. For comparison, the interaction of an E2 conjugating enzyme (UbcH5a) and the RNF4 RING is shown [30] . From Fig. 5B , the location of loop2 of the RING domain is positioned near the zinc ion, the inner surface of the a-helix and closer to the E2 enzyme. In RING domains, residues of loop2 make important contacts with the E2 enzyme [30, 32, 33] . In contrast, loop2 of the B-box1 domain is located away from the zinc ion and towards the outside surface of the a-helix (Fig. 5B) . Therefore, it is possible that the lack of contact between loop2 of the B-box1 domain and the E2 enzyme, caused by the fixed orientation of the loop, may contribute to the weaker E3 ligase activity observed for the wild-type domain.
Removal of the P151-induced restriction of loop2 may allow for the reorientation of residues of loop2 that could contribute to increased contacts with the E2 enzyme. This hypothesis is supported by the observation of enhanced auto-ubiquitination activity of the P151L B-box1 and P151L RB1 and RB1B2 domains. The increased intensities of the mono-ub bands of all three proteins are most consistent with an increase in E3 ligase activity of the P151L mutants. The observation of brighter bands for the mono-ub and less intense bands for the poly-ubiquitinated smearing in Fig. 3A suggest that the mono-ub products are first catalyzed before continuing on to get poly-ubiquitinated.
The observations that the P151L mutation leads to greater E3 ligase activity and a complete loss of polyubiquitination of alpha4 indicate that residue P151 is critical for the binding of alpha4. Therefore, the fixed outward orientation of loop2 is important for binding of alpha4. Previously, we have shown using NMR 1 H-15 N HSQC titrations with the B-box1 and alpha4 proteins that residues on the outer surface of the ahelix and loop2 of the B-box1 domain are involved in the binding of alpha4 [21] . Changing the orientation of loop2 would alter the binding interface and the interaction with alpha4, and hence its ubiquitination.
To independently assess whether the P151L mutation affected the interaction with alpha4, which would explain the loss of poly-ubiquitination, we performed fluorescence studies using the tryptophan residue of alpha4 to monitor binding. Typically, binding in which the tryptophan becomes buried and is less solvent exposed results in an increase in fluorescence at 335 nm. In contrast, no binding will result in little change in fluorescence. Binding studies between the wild-type B-box1 and C-terminal domain of alpha4 (alpha4C) proteins resulted in a significant increase in intensity and a blue shift (from 340 to 335 nm) in fluorescence confirming binding (Fig. 5C ). In contrast, addition of the P151L mutant B-box1 domain to the alpha4C protein resulted in no change in fluorescence intensity indicating no interaction between these proteins (Fig. 5C ). These binding results confirm that loss of poly-ubiquitination of alpha4 was largely due to loss of interaction between the P151L mutant B-box1 and alpha4.
Alpha4 (Iga-BP1/IGBP1) was identified as an immunoglobin binding protein, associating with the MB1 (Iga) B-cell antigen receptor in mammalian T-and Blymphocytes [34] [35] [36] [37] [38] . It is subsequently observed in most cell types and shown to regulate PP2A within the TOR signaling pathway that controls transcription, protein synthesis, cell motility, survival and cell cycle progression in response to nutrients and extracellular stimuli [19, 20, 36, 39] . The X-ray structure of the Nterminal domain of alpha4 (residue 1-220) [40] with a fragment of PP2Ac (res 1-151) reveals distortion of the PP2Ac structure. The inactive conformation of PP2Ac in the complex supports a sequestering mechanism by alpha4. Supporting this sequestration mechanism, we recently showed that the ubiquitination of PP2Ac in the presence of alpha4 was substantially (> 60%) reduced [1] . The mechanism of inhibition is unclear because the inhibition was concentration independent, given that the amount of ubiquitin was high enough to account for the poly-ubiquitination of both proteins. As noted, even though the B-box1 domain is required for the poly-ubiquitination of alpha4, it is not required for targeting PP2Ac [1, 11] . Therefore, we postulate that the increase in PP2A observed in XLOS-derived fibroblasts may be due to an increase in alpha4, which would then bind, sequester and protect PP2Ac from MID1-mediated ubiquitination. In conclusion, our results indicate mutations of the B-box1 domain affect the ubiquitination of alpha4, and given the role of alpha4 in regulating the activity and homeostasis of PP2A, that alpha4 may have a greater role in the pathogenesis of X-linked Opitz Syndrome.
Methods

Protein construction and purification
The cDNA encoding the MID1 B-box1 (110-164), RING-Bbox1 (1-164), RING-B-box1-B-box2 (1-214) and B-box1-B-box2 (110-214) regions were cloned into the pETite vector, allowing for the production of C-terminal His 6 -tagged fusion proteins. The P151L point mutation was introduced by standard PCR protocols. The integrity of the various clones and mutations were confirmed by DNA sequencing before being transformed into Escherichia coli BL21(DE3) cells.
To obtain proteins for biochemical assay and studies, cells were grown at 37°C in Luria Broth (LB) medium and induced with 1 mM isopropyl b-D-1-thiogalactopyranoside for 24 h at 18°C. To obtain isotopically labeled proteins for NMR studies, cells were grown in M9 minimal medium supplemented with 15 N-NH 4 Cl, glucose and vitamins and induced as previously described [25, 41] . Harvested cells were stored in À80°C before re-suspension in 50 mM TRIS (pH 8), 200 mM NaCl, 20 mM b-mercaptoethanol (b-ME), and 1 mM ZnCl 2 . Once homogenous, sarkosyl was added to the suspension to a final concentration of 2% [41] . The cells were further lysed by sonication followed by centrifugation at 20 000 g at 4°C. The His 6 -tagged proteins were purified using standard Ni 2+ -NTA affinity chromatography and dialyzed overnight into 50 mM HEPES (pH 7.5), 150 mM NaCl, 20 mM b-ME, 1 mM ZnCl 2 and 10% glycerol.
NMR studies of P151L mutant B-box1 and B-box1-B-box2 domains N-labeled wild-type and P151L mutant B-box1 and B-box1-B-box2 (B1B2) proteins using a Varian DD2 600 MHz spectrometer equipped with a 5 mm triple resonance probe with z-axis gradient. The NMR data were processed and analyzed using nmrPipe [42] and SPARKY [43] , respectively.
In vitro ubiquitination assays to test activity of the P151L constructs Auto-ubiquitination assays were performed in a total volume of 30 lL containing 1.5 U of thermostable inorganic pyrophosphatase, 1 mM DTT, 5 mM ATP-Mg 2+ , 0.6 lM E1, 30 lM E2 (UbcH5a), and 1 mM N-terminal biotinylated ubiquitin (Ub) in 50 mM Tris-HCl (pH 7.5), and varying concentrations of purified E3 ligase proteins. The assays were performed for 90 min at 30°C and stopped with 2 9 SDS/ PAGE non-reducing (no DTT or b-ME) sample loading buffer. The reaction products were assessed by chemiluminescent western blot analysis, using the anti-biotin antibody. The ubiquitination assays targeting alpha4 were performed similarly to the auto-ubiquitination reactions but using non-biotinylated ubiquitin. The assays with alpha4 were performed at 30°C for 4 h. For western blot analysis, an antibody specific for the C-terminal region of alpha4 (cat #sc-32174) was used.
Fluorescence spectrophotometry
To assess B-box1 and alpha4 binding, tryptophan fluorescence experiments were performed on a Jobin Yvon-Spec Fluoromax-4 Spectrofluorometer (Instruments S.A., Inc., Edison, NJ, USA). Excitation frequency for tryptophan was set at 295 nm and emission was measured between 310 and 410 nm using a 5 nm bandwidth. The C-terminal of alpha4 (alpha4C, 10 lM) was dissolved in 50 mM TRIS (pH 7.5), 150 mM NaCl and 20 mM b-ME. Spectra were acquired of a~1 : 1 ratio of alpha4C to wild-type and P151L mutant B-box1 at 25°C. The fluorescence spectra were corrected with a buffer blank that lacks protein.
